Carisma Therapeutics

Company snapshot

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucia

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Carisma Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Carisma Therapeutics.

1. Jun 5, 2026 Clinical update

   CT-0508 — Phase 1

2. May 23, 2026 Clinical update

   CT-0525 — Phase 1

3. Aug 29, 2023 Patent grant

   Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor

4. Apr 26, 2022 Patent grant

   Constructs for chimeric antigen receptors

View all clinical trial activity →

• What is Carisma Therapeutics?

  Carisma Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker CARM. Primary therapeutic focus areas include HER2-positive. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 2 patent record(s) to this entity from

• Is Carisma Therapeutics publicly traded?

  Yes. Carisma Therapeutics is listed with ticker CARM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Carisma Therapeutics develop or market?

  We link 1 drug profile(s) where Carisma Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/carisma-therapeutics#company-drugs.

• What are the latest developments for Carisma Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Carisma Therapeutics focus on?

  Carisma Therapeutics focuses on HER2-positive based on our analysis of their pipeline programs and drug development activities.